Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10497846rdf:typepubmed:Citationlld:pubmed
pubmed-article:10497846lifeskim:mentionsumls-concept:C0330477lld:lifeskim
pubmed-article:10497846lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:10497846lifeskim:mentionsumls-concept:C0013081lld:lifeskim
pubmed-article:10497846lifeskim:mentionsumls-concept:C0205359lld:lifeskim
pubmed-article:10497846lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:10497846lifeskim:mentionsumls-concept:C0442802lld:lifeskim
pubmed-article:10497846pubmed:issue2lld:pubmed
pubmed-article:10497846pubmed:dateCreated1999-10-26lld:pubmed
pubmed-article:10497846pubmed:abstractTextIn this study, we examined the role of Fas-signaling in the apoptotic pathway in myelodysplastic syndromes (MDS). Ficoll-separated mononuclear cells from 18 bone marrow aspirate specimens obtained from 17 MDS patients, 4 normal healthy donors, and 3 acute myeloid leukemia patients transformed from MDS (t-AML) were studied for mRNA expression of Fas-L, Fas, and the effectors of their signaling, Caspase 1 and Caspase 3, using reverse transcriptase polymerase chain reaction. Fas-L, Fas, and Caspase 1 were detectable in all of the samples in the three groups. Caspase 3 was detectable both in MDS and t-AML specimens but was negligible in normal cells. The apoptotic index (AI%) determined by in situ end labeling of fragmented DNA in 4-hour cultures of mononuclear cells was significantly higher in MDS cells compared to normal or t-AML cells (mean +/- SEM: 2.3% +/- 0.4% in MDS, n = 10 vs. 0.6% +/- 0.2%, n = 4, P = 0.014 in normal cells, and 0.2% +/- 0.2%, n = 3, P = 0.007 in t-AML cells). Treatment of MDS cells with anti-Fas-L antibody suppressed apoptosis (AI%: 2.1% +/- 0.6% in untreated vs. 1.37% +/- 0.5% in treated, n = 6, P = 0.02), indicating functional participation of Fas-signaling in MDS. Further, it was found that Fas-L, Fas, and Caspase 1 mRNA expression remained unchanged in 4 hours. Caspase 3 expression appeared in normal cells after 4 hours and was present at both 0 and 4 hours in MDS and t-AML cells. In contrast to persistent expression in normal and t-AML cells, cells from the 5 MDS patients studied consistently showed significantly lowered or undetectable expression of a negative regulator of Fas, called Fas-associated phosphatase-1 (Fap-1) after 4 hours. Thus, the high AI% in MDS corresponds to a rapid decline in Fap-1. Furthermore, in tumor necrosis factor alpha (TNF-alpha) treated HL60 promyelocytic cells, a definite periodicity in the expression of different mRNAs was observed with upregulation of TNF-alpha itself at 30 minutes, increased expression of Fas and the appearance of Fas-L after 2 hours, and a decrease in Fap-1 expression after 8 hours. These results suggest that TNF-alpha not only induces the effectors of Fas-signaling but also may downregulate the inhibitor. We conclude that a spontaneous and rapid down-regulation of Fap-1, possibly induced by TNF-alpha, a cytokine shown to be present in excess in MDS marrows, may underlie the increased apoptotic death of hematopoietic cells in these patients. Interference with Fap-1 turnover may provide a new therapeutic modality for MDS.lld:pubmed
pubmed-article:10497846pubmed:languageenglld:pubmed
pubmed-article:10497846pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10497846pubmed:citationSubsetIMlld:pubmed
pubmed-article:10497846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10497846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10497846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10497846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10497846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10497846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10497846pubmed:statusMEDLINElld:pubmed
pubmed-article:10497846pubmed:monthAuglld:pubmed
pubmed-article:10497846pubmed:issn0925-5710lld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:VenugopalPPlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:FeldmanGGlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:ShahRRlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:RobinEElld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:RazaAAlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:BagarBBlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:GregoryS ASAlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:ReynAAlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:ShettyVVlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:MungerM AMAlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:MativiB YBYlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:RifkinSSlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:CheemaPPlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:GautamUUlld:pubmed
pubmed-article:10497846pubmed:authorpubmed-author:CartlidgeJ...lld:pubmed
pubmed-article:10497846pubmed:issnTypePrintlld:pubmed
pubmed-article:10497846pubmed:volume70lld:pubmed
pubmed-article:10497846pubmed:ownerNLMlld:pubmed
pubmed-article:10497846pubmed:authorsCompleteYlld:pubmed
pubmed-article:10497846pubmed:pagination83-90lld:pubmed
pubmed-article:10497846pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:meshHeadingpubmed-meshheading:10497846...lld:pubmed
pubmed-article:10497846pubmed:year1999lld:pubmed
pubmed-article:10497846pubmed:articleTitleSpontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.lld:pubmed
pubmed-article:10497846pubmed:affiliationRush Cancer Institute, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA. smundle@rush.edulld:pubmed
pubmed-article:10497846pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10497846lld:pubmed